Novel pharmacological modulators of autophagy and therapeutic prospects

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 9, 2012, Pages 1053-1079

  Bischoff, Pierre ^a   Josset, Elodie ^a   Dumont, Francis J ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

AMPK; Autophagosome; Autophagy; Autophagy enhancer; Autophagy inhibitor; Beclin 1; Cancer; Cell death; Cell survival; MTORC1; Neurodegeneration; ULK complex; Vps34 complex

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; AMIODARONE; ANTINEOPLASTIC AGENT; AUTOPHAGY ENHANCER; AUTOPHAGY INHIBITOR; AZD 8055; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUSPIRILENE; LOPERAMIDE; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NEW DRUG; NICARDIPINE; NIGULDIPINE; PHENOL DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PIMOZIDE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; RSVA 314; SMALL MOLECULE ENHANCER OF RAPAMYCIN; SPHINGOSINE KINASE INHIBITOR; TRIFLUOPERAZINE; UNC 51 LIKE KINASE 1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOSE TISSUE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN; CANCER CELL; DRUG EFFECT; DRUG MECHANISM; ENDOSOME; HEART; HUMAN; IMMUNE SYSTEM; LIVER; LYSOSOME; NERVE CELL; NONHUMAN; PANCREAS; PATENT; PATHOLOGY; PHYSIOLOGICAL PROCESS; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; SKELETAL MUSCLE;

ANIMALS; AUTOPHAGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HOMEOSTASIS; HUMANS; LYSOSOMES; ORGANELLES; PATENTS AS TOPIC;

EID: 84865451717     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.715148     Document Type: Review

References (147)

1. Yang Z, Klionsky DJ. Mammalian autophagy: Core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010;22:124-31
2. Mizushima N, Komatsu M. Autophagy: Renovation of cells and tissues. Cell 2011;147:728-41. Up-to-date overview of the physiological role of autophagy in metabolic adaptation and the maintenance of intracellular integrity through degradation and replacement of damaged constituents. The possible contribution of dysfunctional autophagy in the pathogenesis of diverse diseases is also discussed.
3. Singh R, Cuervo AM. Autophagy in the cellular energetic balance. Cell Metab 2011;13:495-504
4. Kroemer G, Marino G, Levine B. Autophagy and the integrated stress response. Mol Cell 2010;40:280-93
5. Ravikumar B, Sarkar S, Davies JE, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010;90:1383-435. Provides an overview of the autophagic machinery and its mechanisms of regulation under normal physiological conditions and reviews the evidence indicating that malfunction of autophagy is associated with a number of human diseases.
6. Denton D, Nicolson S, Kumar S. Cell death by autophagy: Facts and apparent artefacts. Cell Death Differ 2012;19:87-95
7. Sridhar S, Botbol Y, Macian F, Cuervo AM. Autophagy and disease: Always two sides to a problem. J Pathol 2012;226:255-73. This review of current knowledge on the status of autophagic processes in diverse pathological conditions points to the fact that autophagy can often exert both beneficial and aggravating effects on disease progression. What determines the switch between these opposite roles of autophagy remains to be defined in future investigations.
8. Rubinsztein DC, Marino G, Kroemer G. Autophagy and aging. Cell 2011;146:682-95
9. Fleming A, Noda T, Yoshimori T, Rubinsztein DC. Chemical modulators of autophagy as biological probes and potential therapeutics. Nat Chem Biol 2011;7:9-17. A review of chemical agents that are known to induce or enhance autophagy and may be used for the therapy of neurodegenerative diseases.
10. Baek KH, Park J, Shin I. Autophagy-regulating small molecules and their therapeutic applications. Chem Soc Rev 2012;41:3245-63. Comprehensive review of the existing small molecule inhibitors and activators of autophagy and their utility as probes for mechanistic analyses of autophagy or potential therapeutic agents.
11. Alers S, Loffler AS, Wesselborg S, Stork B. The incredible ULKs. Cell Commun Signal 2012;10:7
12. Sengupta S, Peterson TR, Sabatini DM. Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310-22
13. Laplante M. Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-93. This is a comprehensive and up-to-date review of the various cellular processes regulated by the mTOR signaling network.
14. Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/ 2 in the regulation of autophagy: Cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2-11
15. Yeda Research and Development Co Ltd. Death associated protein 1 variants and use thereof for modulating autophagy. WO2011111051; 2011
16. Koren I, Reem E, Kimchi A. DAP1, a novel substrate of mTOR, negatively regulates autophagy. Curr Biol 2010;20:1093-8
17. Fondazione Telethon. Molecules able to modulate the expression of at least a gene involved in degradative pathways and uses thereof. WO2010092112; 2010
18. Settembre C, Zoncu R, Medina DL, et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J 2012;31:1095-108
19. Kang R, Zeh HJ, Lotze MT, Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011;18:571-80
20. Di Bartolomeo S, Corazzari M, Nazio F, et al. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J Cell Biol 2010;191:155-68
21. Mount Sinai School of Medicine of NYU, The Rockefeller University. Novel autophagy regulators Atg14L and Rubicon. WO2010030936; 2010
22. Sun Q, Zhang J, Fan W, et al. The RUN domain of rubicon is important for hVps34 binding, lipid kinase inhibition, and autophagy suppression. J Biol Chem 2011;286:185-91
23. Lipinski MM, Hoffman G, Ng A, et al. A genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways regulating autophagy under normal nutritional conditions. Dev Cell 2010;18:1041-52. This important study demonstrates that under normal homeostatic conditions Vps34 regulates autophagy in an mTORC1-independent manner by integrating multiple signals from growth factors and cytokines. It also indicates that cell proliferation and autophagy are regulated in a mutually exclusive fashion by these signals.
24. President and Fellows of Harvard College. Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products. WO2011041584; 2011
25. President and Fellows of Harvard College. Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products. WO2011041582; 2011
26. Harris H, Rubinsztein DC. Control of autophagy as a therapy for neurodegenerative disease. Nat Rev Neurol 2011;8:108-17
27. Hidvegi T, Ewing M, Hale P, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010;329:229-32
28. Lefranc F, Ingrassia L, Kiss R. Targeting autophagy: Do patents reveal a therapeutic potential? Expert Opin Ther Patents 2008;18:813-19
29. Nyfeler B, Bergman P, Triantafellow E, et al. Relieving autophagy and 4EBP1 from rapamycin resistance. Mol Cell Biol 2011;31:2867-76
30. Chresta CM, Davies BR, Hickson I, et al. AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 2010;70:288-98
31. Fan QW, Cheng C, Hackett C, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010;3:ra81
32. The Salk Institute for Biological Studies. ULK1 compositions, inhibitors, screening and methods of use. WO2011084523; 2011
33. Vingtdeux V, Chandakkar P, Zhao H, et al. Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-beta peptide degradation. FASEB J 2011;25:219-31
34. Maiuri MC, Le Toumelin G, Criollo A, et al. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 2007;26:2527-39 (Pubitemid 46788315)
35. Chipuk JE, Moldoveanu T, Llambi F, et al. The BCL-2 family reunion. Mol Cell 2010;37:299-310
36. University of Florida Research Foundation. Methods and compositions for the treatment of cancers and pathogenic infections. WO2011019636; 2011
37. Oberstein A, Jeffrey PD, Shi Y. Crystal structure of the Bcl-XL-Beclin 1 peptide complex: Beclin 1 is a novel BH3-only protein. J Biol Chem 2007;282:13123-32 (Pubitemid 47100641)
38. Fondazione Santa Lucia. Peptidic and peptidomimetic compounds for regulating autophagy. WO2010018182; 2010
39. Vergne I, Deretic V. The role of PI3P phosphatases in the regulation of autophagy. FEBS Lett 2010;584:1313-18
40. Van Andel Research Institute. Method for treating autophagy-related disorders. WO2010129681; 2010
41. Eisenberg T, Knauer H, Schauer A, et al. Induction of autophagy by spermidine promotes longevity. Nat Cell Biol 2009;11:1305-14. Demonstrates that spermidine is capable of markedly extending the lifespan of yeast, flies and worms through the upregulation of autophagy.
42. Katholieke Universiteit Leuven. Polyamine activators (spermine, spermidine) of the autophagic pathway. WO2010081204; 2010
43. Morselli E, Marino G, Bennetzen MV, et al. Spermidine and resveratrol induce autophagy by distinct pathways converging on the acetylproteome. J Cell Biol 2011;192:615-29. This study provides insight into the mechanism by which spermidine and resverastrol enhance autophagy, and reveals that cytoplasmic acetylation/ deacetylation reactions play an important role in regulating the autophagic cascade.
44. President and Fellows of Harvard College, Dana Farber Cancer Institute, Cambridge Enterprise Ltd. Regulating autophagy. WO2008122038; 2008
45. Sarkar S, Perlstein EO, Imarisio S, et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007;3:331-8. Reports the discovery of SMERs compounds that can induce autophagy by acting either independently or downstream of mTORC1 and are able to attenuate the toxicity of mutant huntingtin-fragment in Huntington's disease cells.
46. Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J 2011;25:1934-44
47. Floto RA, Sarkar S, Perlstein EO, et al. Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages. Autophagy 2007;3:620-2 (Pubitemid 350060063)
48. President and Fellows of Harvard College, Shangai Institute of organic chemistry. Autophagy inducing compounds and uses thereof in treating autophagy associated diseases. WO2009049242; 2009
49. Zhang L, Yu J, Pan H, et al. Small molecule regulators of autophagy identified by an image-based highthroughput screen. Proc Natl Acad Sci USA 2007;104:19023-8
50. President and Fellows of Harvard College, Shanghai Institute of Organic Chemistry. Diphenylbutypiperidine autophagy inducers. WO2011143444; 2011
51. Xia HG, Zhang L, Chen G, et al. Control of basal autophagy by calpain1 mediated cleavage of ATG5. Autophagy 2010;6:61-6
52. Cambridge Enterprise Ltd. Modulation of autophagy by calpain inhibition. WO2007003941; 2007
53. Tsvetkov AS, Miller J, Arrasate M, et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc Natl Acad Sci USA 2010;107:16982-7
54. Bedia C, Levade T, Codogno P. Regulation of autophagy by sphingolipids. Anticancer Agents Med Chem 2011;11:844-53
55. Apogee Biotechnology Corp. X. Sphingosine kinase inhibitors. US8063248; 2011
56. Beljanski V, Knaak C, Smith CD. A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 2010;333:454-64
57. Young M, Takahashi Y, Khan O, et al. Autophagosomal membrane serves as a platform for an intracellular death-inducing signaling complex (iDISC)-mediated caspase-8 activation and apoptosis. J Biol Chem 2012;287:12455-1268
58. Beljanski V, Knaak C, Zhuang Y, Smith CD. Combined anticancer effects of sphingosine kinase inhibitors and sorafenib. Invest New Drugs 2011;29:1132-42
59. ABC294640 in treating patients with advanced solid tumors (ABC-101). Available from: Http://clinicaltrials.gov/ ct2/results?term=abc294640 [Last accessed 17 July 2012]
60. Novogen Research PTY Ltd. Method for inducing autophagy. WO2008113100; 2008
61. Alvero AB, Montagna MK, Chen R, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through the Akt/mammalian target of rapamycin pathway. Cancer 2009;115:3204-16
62. Alvero AB, Montagna MK, Holmberg JC, et al. Targeting the mitochondria activates two independent cell death pathways in ovarian cancer stem cells. Mol Cancer Ther 2011;10:1385-93. Demonstrates that NV128 can induce both autophagy and apoptotic cell death in chemotherapy-resistant ovarian cancer stem cells by disrupting mitochondrial function, and thereby promoting a state of cellular starvation. This compound may offer a new approach to treat recalcitrant ovarian cancers.
63. Marshall Edwards announces first cohort of patients dosed in Phase I clinical trial of oncology drug candidate ME-344. Available from: Http://www.meipharma. com/news/2012/05/29/ Last accessed 17 July 2012]
64. Lee JS, Li Q, Lee JY, et al. FLIP-mediated autophagy regulation in cell death control. Nat Cell Biol 2009;11:1355-62
65. University of Southern California. FLIP death effector domain derived peptides for inducing autophagy. WO201011952; 2010
66. University of Southern California. Highly potent peptides to control cancer and neurodegenerative diseases. WO20120158386; 2012
67. Tormo D, Checinska A, Alonso-Curbelo D, et al. Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 2009;16:103-14. This important study demonstrates that intracellular delivery of Poly-IC can induce autophagy and apoptotic cell death in melanoma cells through activation of the dsRNA sensor MDA-5 and the proapoptotic protein NOXA.
68. Fundacion Centro Nacional de investigaciones oncolgicas Carlos III. Process for the identification of compounds for treating cancer. WO2011003883; 2011
69. Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell 2011;42:23-35
70. Tang Y, Hamed HA, Cruickshanks N, et al. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA. Mol Pharmacol 2012;81:527-40
71. Inao T, Harashima N, Monma H, et al. Antitumor effects of cytoplasmic delivery of an innate adjuvant receptor ligand, poly(I:C), on human breast cancer. Breast Cancer Res Treat 2012;134:89-100
72. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009;76:939-45
73. Leland Stanford Junior University, Auckland Uniservices Ltd. Heteroaryl compounds, compositions, and methods of use in cancer treatment. WO2009114552; 2009
74. Turcotte S, Chan DA, Sutphin PD, et al. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy. Cancer Cell 2008;14:90-102. Along with [73], this paper reports on the identification of STF-62247 that induces autophagy-dependent cell death and reduced tumor growth of VHL-deficient renal carcinoma cells but not their VHL-sufficient counterparts. This may open the way to a paradigm shift in cancer therapy whereby malignant cells can be selectively targeted through synthetic lethality. (Pubitemid 351885499)
75. Anbalagan S, Pires IM, Blick C, et al. Radiosensitization of renal cell carcinoma in vitro through the induction of autophagy. Radiother Oncol 2012;103:388-93
76. Hay MP, Turcotte S, Flanagan JU, et al. 4-Pyridylanilinothiazoles that selectively target von Hippel-Lindau deficient renal cell carcinoma cells by inducing autophagic cell death. J Med Chem 2010;53:787-97
77. Bonnet M, Flanagan JU, Chan DA, et al. SAR studies of 4-pyridyl heterocyclic anilines that selectively induce autophagic cell death in von Hippel-Lindau-deficient renal cell carcinoma cells. Bioorg Med Chem 2011;19:3347-56
78. Butler D, Hwang J, Estick C, et al. Protective effects of positive lysosomal modulation in Alzheimer's disease transgenic mouse models. PLoS One 2011;6:e20501
79. University of Connecticut. Compounds for lysosomal modulation and methods of use. WO2009129532; 2009
80. Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011;8:528-39. Reviews the evidence that autophagy can both suppress cancerogenesis at an early stage and promote tumor progression by enabling cancerous cells to survive and during unfavorable metabolic conditions. How this dual role of autophagy may impact cancer therapy is also discussed.
81. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res 2011;17:654-66. This review examines the functional relevance of autophagy within the tumor microenvironment and provides an update of the ongoing clinical trials using HCQ for adjunct cancer therapy.
82. Eng CH, Abraham RT. The autophagy conundrum in cancer: Influence of tumorigenic metabolic reprogramming. Oncogene 2011;30:4687-96. This excellent review discusses the role of the metabolic reprogramming associated with tumorigenesis in mediating an autophagic response that promotes tumor cell survival and the possibility of exploiting this response to target tumor cells with autophagy inhibitors.
83. The University of Medicine and Dentistry of New Jersey. Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor. WO20110022236; 2010
84. US Department of Health and Human Services. Disabling autophagy as a treatment for lysosomal storage diseases. WO2011028941; 2011
85. Mount Sinai School of Medicine. Methods and compositions for inhibiting autophagy for the treatment of fibrosis. WO2012037547; 2012
86. Miller S, Tavshanjian B, Oleksy A, et al. Shaping development of autophagy inhibitors with the structure of the lipid kinase Vps34. Science 2010;327:1638-42 This paper describes the crystal structure of Vps34, revealing a uniquely constricted ATP-binding pocket and suggesting that Vps34 may alternate between a closed cytosolic form and an open form on the membrane. Using this structural information, a PI3K inhibitor acting preferentially on Vps34 versus Class I PI3K was synthesized, thus indicating the feasibility of developing specific Vps34 inhibitors.
87. This paper describes the crystal structure of Vps34, revealing a uniquely constricted ATP-binding pocket and suggesting that Vps34 may alternate between a closed cytosolic form and an open form on the membrane. Using this structural information, a PI3K inhibitor acting preferentially on Vps34 versus Class I PI3K was synthesized, thus indicating the feasibility of developing specific Vps34 inhibitors. 87. Novartis AG. Bi-heteroaryl compounds as vps34 inhibitors. WO2012085815; 2012
88. Zhu H, Wu H, Li X, et al. Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells. Autophagy 2009;5:816-23
89. Korkmaz G, le Sage C, Tekirdag KA, et al. miR-376b controls starvation and mTOR inhibition-related autophagy by targeting ATG4C and BECN1. Autophagy 2012;8:165-76
90. Sabanci Universitesi. Use of miRNAs for the diagnosis, prophylaxis, treatment and follow-up of diseases involving macroautophagy abnormalities. WO2012044265; 2012
91. McDermott AM, Heneghan HM, Miller N, Kerin MJ. The therapeutic potential of microRNAs: Disease modulators and drug targets. Pharm Res 2011;28:3016-29
92. President and Fellows of Harvard College, Shangai Institute of organic chemistry. Potent small molecule inhibitors of autophagy, and methods of use thereof. WO2011011522; 2011. Along with [93], this patent discloses Spautin-1, a novel type of small molecule inhibitor of autophagy that promotes the proteosomal degradation of Beclin-1 by interfering with its deubiquination. Spautin-1 also promotes p53 degradation and induces apoptosis of glucose-starved cancer cells but not normal cells and may thus provide a lead compound for developing a novel type of anticancer agents.
93. Liu J, Xia H, Kim M, et al. Beclin1 controls the levels of p53 by regulating the deubiquitination activity of USP10 and USP13. Cell 2011;147:223-34. Along with [92], this landmark paper describes the discovery and biological characterization of Spautin-1, a novel type of small molecule inhibitor of autophagy that promotes the proteosomal degradation of Beclin-1 by interfering with its deubiquination. Spautin-1 also promotes p53 degradation and induces apoptosis of glucose-starved cancer cells but not normal cells and may thus provide a lead compound for developing a novel type of anticancer agents.
94. Tanida I, Sou YS, Ezaki J, et al. HsAtg4B/HsApg4B/autophagin-1 cleaves the carboxyl termini of three human Atg8 homologues and delipidates microtubule-associated protein light chain 3- and GABAA receptor-associated protein-phospholipid conjugates. J Biol Chem 2004;279:36268-76 (Pubitemid 39128963)
95. Li M, Hou Y, Wang J, et al. Kinetics comparisons of mammalian Atg4 homologues indicate selective preferences toward diverse Atg8 substrates. J Biol Chem 2011;286:7327-38
96. University of Florida Research Foundation. Methods and compositions for the treatment of cancers and pathogenic infections. WO2009089147; 2009
97. Kumanomidou T, Mizushima T, Komatsu M, et al. The crystal structure of human Atg4b, a processing and de-conjugating enzyme for autophagosome-forming modifiers. J Mol Biol 2006;355:612-18 (Pubitemid 41817622)
98. Satoo K, Noda NN, Kumeta H, et al. The structure of Atg4B-LC3 complex reveals the mechanism of LC3 processing and delipidation during autophagy. EMBO J 2009;28:1341-50
99. Shu CW, Madiraju C, Zhai D, et al. High-throughput fluorescence assay for small-molecule inhibitors of autophagins/ Atg4. J Biomol Screen 2011;16:174-82
100. Li M, Chen X, Ye QZ, et al. A high-throughput FRET-based assay for determination of Atg4 activity. Autophagy 2012;8:401-12
101. San Diego State University Foundation. Compositions and methods for modulating autophagy. WO2011106684; 2011
102. Gottlieb RA, Mentzer RMJ. Cardioprotection through autophagy: Ready for clinical trial? Autophagy 2011;7:434-5
103. The University of British Columbia. Autophagy inhibitor compounds, compositions and methods for the use thereof in the treatment of cancer. WO2011017809; 2011
104. Donohue E, Tovey A, Vogl AW, et al. Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 2011;286:7290-300. Shows that verteporfin can inhibit autophagosome formation by acting downstream of LC3 processing and lipidation, thereby preventing starvation-induced autophagic degradation. As verteporfin reduces the viability of cancer cells grown in nutrient-depletion but not nutrient-rich conditions, is relatively safe in absence of light exposure and is already approved for clinical use, it deserves evaluation as a potential adjunct to cancer therapy.
105. The General Hospital Corp. Autophagic compounds and tyrosine kinase inhibitors for treating cancer. WO2008036254; 2008
106. University of Colorado. Methods and products for treating proliferative diseases. WO2010008554; 2010
107. The Trustees of the University of Pennsylvania. Combination antineoplastic therapy. WO2010132233; 2010
108. Exelixis, Inc., The Regents of the University of California. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K amd mTOR in combination with autophagy inhibitors. WO2011100319; 2011
109. Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms. WO2012087336; 2012
110. Maycotte P, Aryal S, Cummings CT, et al. Chloroquine sensitizes breast cancer cells to chemotherapy independent of autophagy. Autophagy 2012;8:200-12
111. Amaravadi R. Autophagy inhibition in cancer therapy: Progress and unaswered questions. AAAS Annual Meeting 16-20 February 2012. Vancouver, Canada. Available from: Http://aaas. confex.com/aaas/2012/webprogram/ Paper6717.html [Last accessed 17 July 2012]
112. McAfee Q, Zhang Z, Samanta A, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA 2012;109:8253-8. Demonstrates that a novel bisaminoquinoline derivative of HCQ potently inhibits autophagy and exerts single-agent anticancer activity without overt toxicity in a tumor xenograft model.
113. Naidu MD, Mason JM, Pica RV, et al. Radiation resistance in glioma cells determined by DNA damage repair activity of Ape1/Ref-1. J Radiat Res (Tokyo) 2010;51:393-404
114. Spectrum Pharmaceuticals, Inc Thioxantone-based autophagy inhibitor therapies to treat cancer. WO2011112623; 2011
115. Carew JS, Espitia CM, Esquivel JA, et al. Lucanthone is a novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis. J Biol Chem 2011;286:6602-13
116. Safety and efficacy study of lucanthone when used in combination with temozolomide(TMZ) and radiation to treat glioblastoma multiforme(GBM). Available from: Http://clinicaltrials.gov/ ct2/results?term=lucanthone [Last accessed 17 July 2012]
117. University of Manitoba. The use of glycosylated antitumor ether lipids to induce and/or enhance autophagy for treatment of diseases. WO2009092170; 2009
118. Jahreiss L, Renna M, Bittman R, et al. 1-O-Hexadecyl-2-O-methyl-3-O-(2'- acetamido-2'-deoxy-beta-Dglucopyranosyl)- sn-glycerol (Gln) induces cell death with more autophagosomes which is autophagy-independent. Autophagy 2009;5:835-46. This study illustrates the pitfalls of using autophagosome formation only as a parameter of autophagic flux activation and shows that Gln augments the accumulation of autophagosomes not by activating autophagy but by blocking autophagosone maturation and lysosomal degradative function, thereby causing tumor cell death via lysosomal cathepsin leakage into the cytoplasm.
119. Behrends C, Sowa ME, Gygi SP, Harper JW. Network organization of the human autophagy system. Nature 2010;466:68-76
120. Lipinski MM, Zheng B, Lu T, et al. Genome-wide analysis reveals mechanisms modulating autophagy in normal brain aging and in Alzheimer's disease. Proc Natl Acad Sci USA 2010;107:14164-9. This important study demonstrates that whereas autophagy tends to decrease during normal brain aging, it is upregulated in Alzheimer's disease patients. Since autophagy contributes to amyloid-b formation, this suggests that inhibiting autophagy at an early stage and/or enhancing autolysosome formation and degradative capacity may be desirable to combat Alzheimer's disease.
121. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 2011;43:38-45
122. Duke University. Therapeutic agents for neurodegenerative diseases. WO2011066430; 2011
123. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;14:859-63 (Pubitemid 46920134)
124. Gonzalez P, Mader I, Tchoghandjian A, et al. Impairment of lysosomal integrity by B10, a glycosylated derivative of betulinic acid, leads to lysosomal cell death and converts autophagy into a detrimental process. Cell Death Differ 2012;19:1337-46
125. Reggiori F, Komatsu M, Finley K, Simonsen A. Autophagy: More than a nonselective pathway. Int J Cell Biol 2012;2012:219625
126. Juenemann K, Reits EA. Alternative macroautophagic pathways. Int J Cell Biol 2012;2012:189794
127. Codogno P, Mehrpour M, Proikas-Cezanne T. Canonical and non-canonical autophagy: Variations on a common theme of self-eating? Nat Rev Mol Cell Biol 2012;13:7-12
128. Edelmann MJ, Nicholson B, Kessler BM. Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases. Expert Rev Mol Med 2011;13:e35
129. Hamai A, Codogno P. New targets for acetylation in autophagy. Sci Signal 2012;5:pe29
130. Czaja MJ. Functions of autophagy in hepatic and pancreatic physiology and disease. Gastroenterology 2011;140:1895-908
131. Nemchenko A, Chiong M, Turer A, et al. Autophagy as a therapeutic target in cardiovascular disease. J Mol Cell Cardiol 2011;51:584-93
132. Sandri M. Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. Am J Physiol Cell Physiol 2010;298:C1291-7
133. Czaja MJ. Autophagy in health and disease. 2. Regulation of lipid metabolism and storage by autophagy: Pathophysiological implications. Am J Physiol Cell Physiol 2010;298:C973-8
134. Kovsan J, Bluher M, Tarnovscki T, et al. Altered autophagy in human adipose tissues in obesity. J Clin Endocrinol Metab 2011;96:E268-77
135. Fujitani Y, Ueno T, Watada H. Autophagy in health and disease. 4. The role of pancreatic beta-cell autophagyin health and diabetes. Am J Physiol Cell Physiol 2010;299:C1-6
136. Levine B, Mizushima N, Virgin HW. Autophagy in immunity and inflammation. Nature 2011;469:323-35
137. Yeda Research and Development Co Ltd. Compositions and methods for diagnosing and treating cancer and neurodegenerative diseases related to Beclin-1. WO2010064250; 2010
138. University of Rochester. Methods and compositions related to modulating autophagy. WO2011146879; 2011
139. Available from: Http://www.bioncotech. com/es/ [Last accessed 17 July 2012]
140. Available from: Http://www.rugacorp. com/Pipeline.html [Last accessed 17 July 2012]
141. Jaber N, Dou Z, Chen JS, et al. Class III PI3K Vps34 plays an essential role in autophagy and in heart and liver function. Proc Natl Acad Sci USA 2012;109:2003-8
142. Ktistakis NT, Manifava M, Schoenfelder P, Rotondo S. How phosphoinositide 3-phosphate controls growth downstream of amino acids and autophagy downstream of amino acid withdrawal. Biochem Soc Trans 2012;40:37-43
143. Cosford N. Targeting kinases regulating sensitivity to anti-estrogens and autophagy. Available from: Http:// sanfordburnham.flintbox.com/public/project/ 19714/ [Last accessed 17 July 2012]
144. Young RN, Arns S, Gorski SM, et al. Novel assays and inhibitors of the key autophagy protease. AAAS Annual Meeting 16-20 February 2012. Vancouver, Canada. Available from: Http://aaas.confex.com/aaas/2012/ webprogram/Paper6715. html [Last accessed 17 July 2012]
145. Noda NN, Satoo K, Fujioka Y, et al. Structural basis of Atg8 activation by a homodimeric E1, Atg7. Mol Cell 2011;44:462-75
146. Taherbhoy AM, Tait SW, Kaiser SE, et al. Atg8 transfer from Atg7 to Atg3: A distinctive E1-E2 architecture and mechanism in the autophagy pathway. Mol Cell 2011;44:451-61
147. D'Amore N. Autophagy research: An industrial perspective. AAAS Annual Meeting 16-20 February 2012. Vancouver, Canada. Available from: Http://aaas.confex.com/aaas/2012/ webprogram/Paper6616.html [Last accessed 17 July 2012]